Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab

Am J Ther. 2020 Jul/Aug;27(4):e415-e417. doi: 10.1097/MJT.0000000000001165.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Colitis / chemically induced*
  • Colitis / drug therapy*
  • Humans
  • Infliximab / therapeutic use*
  • Ipilimumab / adverse effects*
  • Ipilimumab / therapeutic use
  • Male
  • Melanoma / drug therapy
  • Nivolumab / adverse effects*
  • Nivolumab / therapeutic use

Substances

  • Ipilimumab
  • Nivolumab
  • Infliximab